Peer-reviewed veterinary case report
Blood test using microRNAs to classify and predict lymphoma in dogs
By Ludwig, Latasha et al.·Published in Veterinary and comparative oncology·2025·Department of Pathobiology, Canada·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Classification and Prognostication of B-Cell and T-Cell Multicentric Lymphoma in Dogs Using Serum MicroRNAs.
- Species:
- dog
Plain-English summary
A dog with multicentric lymphoma, a common type of cancer, often responds well to initial chemotherapy but may relapse and have a poor response to further treatments. Researchers studied small molecules called microRNAs in the blood of dogs with B-cell and T-cell lymphomas to help differentiate between these types and predict outcomes. They found specific microRNAs that could accurately classify the lymphoma types and even predict survival rates for dogs receiving standard chemotherapy. This new approach could help veterinarians diagnose lymphoma more effectively and tailor treatment plans based on the dog's specific cancer type.
People also search for: dog lymphoma treatment · dog cancer prognosis · B-cell lymphoma in dogs · microRNA testing for dogs
Abstract
Canine multicentric lymphoma is a common malignancy in dogs. It often responds well to initial chemotherapy but frequently relapses and has a poor response to subsequent treatment. B-cell (BCL) and T-cell (TCL) lymphomas differ in both their prognoses and chemotherapeutic treatment protocols. Currently, immunophenotyping can be costly and can only be performed on specific high-quality samples. MicroRNAs (miRNAs) are small molecules present in blood and tissues and are dysregulated in both human and canine lymphoma. We investigated 59 miRNAs by RT-qPCR to establish a serum miRNA profile in dogs with B-cell and T-cell multicentric lymphoma. Multiple miRNA pruned decision tree models were used to classify BCL and TCL cases from each other and controls, and to predict prognosis in BCL cases receiving standard CHOP chemotherapy. Six individual miRNAs were differentially expressed in serum between BCL and controls, and three were differentially expressed between BCL and TCL. A three-miRNA model (miR-155-5p, miR-1 and miR-181b) could differentiate between BCL, TCL and control samples with an accuracy of 83.02%. A three-miRNA model (miR-125b-5p, miR-350 and let-7b-5p) in BCL samples separated the cases into four groups with hazard ratios ranging from 0.44 to 3.5 for overall survival. This study established a serum miRNA profile for both BCL and TCL and demonstrated the utility of multiple serum miRNA models to assist in the diagnosis of lymphoma and BCL prognostication.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40186510/